title: HLA-matched sibling stem cell transplantation in children with β-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience.
abstract: BU combined with CY, the preferred preparatory regimen for thalassemic patients, is associated with a substantial incidence of graft rejection especially in patients with advanced disease stage. This study retrospectively analyzes the outcome of 75 consecutive pediatric patients with β-thalassemia who underwent HLA-matched sibling transplantation after anti-thymocyte globulin (ATG)-containing myeloablative conditioning regimens. With a median follow-up of 9 years (range 1-15 years), the overall survival (OS) and thalassemia free survival (TFS) rates were 96% and 92%, respectively. Both the estimated TRM and the cumulative incidence of rejection/failure were 4%. The cumulative incidences of acute GVHD grade II-III and grade III were 20% and 5.3%, respectively. No patient developed acute GVHD grade IV. Only two patients developed extensive chronic GVHD. The estimated OS and TFS for patients with Class 1 and 2 disease according to Pesaro criteria were 96.3% and 94.4%, whereas for patients with Class 3 disease they were 94.1% and 88.2%, respectively. In our series, the use of myeloablative conditioning regimens, which include ATG for the transplantation of thalassemic children from matched sibling donors, resulted in excellent outcomes with very low incidences of TRM and rejection.
authors.affiliation: Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Thivon and Papadiamantopoulou, Athens, Greece. evgoussetis@gmail.com
authors.forename: E
authors.initials: E
authors.lastname: Goussetis
authors.forename: I
authors.initials: I
authors.lastname: Peristeri
authors.forename: V
authors.initials: V
authors.lastname: Kitra
authors.forename: G
authors.initials: G
authors.lastname: Vessalas
authors.forename: A
authors.initials: A
authors.lastname: Paisiou
authors.forename: M
authors.initials: M
authors.lastname: Theodosaki
authors.forename: E
authors.initials: E
authors.lastname: Petrakou
authors.forename: M N
authors.initials: MN
authors.lastname: Dimopoulou
authors.forename: S
authors.initials: S
authors.lastname: Graphakos
mesh_terms: D000293:Adolescent; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology / Q000401:mortality / Q000628:therapy; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000628:therapy; D006115:Greece / Q000453:epidemiology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007223:Infant; D019520:Living Donors; D008297:Male; D012189:Retrospective Studies; D035781:Siblings; D033581:Stem Cell Transplantation; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D017086:beta-Thalassemia / Q000401:mortality* / Q000628:therapy*
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents